|
|
 |
|
Viewing report
|
|
|
|
Mergers and Acquisitions, Partnerships, and Collaborations Review and Outlook 2011
UBM Canon, Jan 2011, Pages: 109
Product diversification remains a significant growth strategy in the pharma world as demonstrated by 2010’s largest healthcare M&A transaction, Novartis AG’s acquisition of Alcon Inc. For a total of $51.6 billion, Novartis will merge Alcon into its fold and become the premiere player in the worldwide eye-health arena. The merger is anticipated to be finalized during first-half 2011. Implementation is expected to take six months from the closing of the merger.
Following the completed merger, Alcon will be the new eye-care division of Novartis. The business will include CIBA Vision and ophthalmic medicines. Alcon and Novartis have attractive worldwide eye-care activities, each offering their own competitive positions in highly complementary segments that combined cover more than 70% of the global vision-care market. Aligning these strengths will create an offering of even more compelling products for patients around the globe.
According to Novartis, the new eye-care division will have enhanced opportunities to accelerate expansion in high-growth regions, generate greater value from combined product portfolios, and capitalize on strengthened R&D capabilities. Boston Scientific continues to show commitment in providing the broadest portfolio of less-invasive devices for cardiovascular care. Boston Scientific recently acquired Atritech, a privately held company based in Plymouth, Minn. This deal is centered around Atritech's newest product, a device designed to close the left atrial appendage in patients with atrial fibrillation who are at risk for ischemic stroke.
The $375 million deal is anticipated to be completed in the first quarter of 2011. Another deal anticipated to be finalized in 2011 is the acquisition of U.S. biotech firm Genzyme by French pharma giant Sanofi-Aventis. The European Union has recently announced its approval for the proposed $18.5 billion deal.
This special report includes analysis of the total healthcare arena’s top 10 mergers and acquisitions during 2010, provides a comprehensive listing of healthcare companies’ M&A activity throughout the many different industry segments for last year, and details the 2010 deals for the top 20 companies within each of these sectors: Pharmaceutical, Biotechnology, Specialty and Medical Device.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
|
|
|
|
